Broad-spectrum non-nucleoside inhibitors for caliciviruses

Natalie E Netzler, Daniel Enosi Tuipulotu, Auda A Eltahla, Jennifer H Lun, Salvatore Ferla, Andrea Brancale, Nadya Urakova, Michael Frese, Tanja Strive, Jason M Mackenzie, Peter A White

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Viruses of the Caliciviridae cause significant and sometimes lethal diseases, however despite substantial research efforts, specific antivirals are lacking. Broad-spectrum antivirals could combat multiple viral pathogens, offering a rapid solution when no therapies exist. The RNA-dependent RNA polymerase (RdRp) is an attractive antiviral target as it is essential for viral replication and lacks mammalian homologs. To focus the search for pan-Caliciviridae antivirals, the RdRp was probed with non-nucleoside inhibitors (NNIs) developed against hepatitis C virus (HCV) to reveal both allosteric ligands for structure-activity relationship enhancement, and highly-conserved RdRp pockets for antiviral targeting. The ability of HCV NNIs to inhibit calicivirus RdRp activities was assessed using in vitro enzyme and mouse norovirus cell culture assays. Results revealed that three NNIs which bound the HCV RdRp Thumb I (TI) site also inhibited transcriptional activities of six RdRps spanning the Norovirus, Sapovirus and Lagovirus genera of the Caliciviridae. These NNIs included JTK-109 (RdRp inhibition range: IC50 4.3-16.6 μM), TMC-647055 (IC50 range: 18.8-45.4 μM) and Beclabuvir (IC50 range: 23.8->100 μM). In silico studies and site-directed mutagenesis indicated the JTK-109 binding site was within the calicivirus RdRp thumb domain, in a pocket termed Site-B, which is highly-conserved within all calicivirus RdRps. Additionally, RdRp inhibition assays revealed that JTK-109 was antagonistic with the previously reported RdRp inhibitor pyridoxal-5'-phosphate-6-(2'-naphthylazo-6'-nitro-4',8'-disulfonate) tetrasodium salt (PPNDS), that also binds to Site-B. Moreover, like JTK-109, PPNDS was also a potent inhibitor of polymerases from six viruses spanning the three Caliciviridae genera tested (IC50 range: 0.1-2.3 μM). Together, this study demonstrates the potential for de novo development of broad-spectrum antivirals that target the highly-conserved RdRp thumb pocket, Site-B. We also revealed three broad-spectrum HCV NNIs that could be used as antiviral scaffolds for further development against caliciviruses and other viruses.

Original languageEnglish
Pages (from-to)65-75
Number of pages11
JournalAntiviral Research
Volume146
Early online date27 Jul 2017
DOIs
Publication statusPublished - 1 Oct 2017

Fingerprint

RNA Replicase
Caliciviridae
Antiviral Agents
Hepacivirus
Inhibitory Concentration 50
Thumb
Norovirus
Viruses
Lagovirus
Sapovirus
RNA Polymerase I
Structure-Activity Relationship
Site-Directed Mutagenesis
Computer Simulation
Cell Culture Techniques
Salts
Binding Sites
Ligands

Cite this

Netzler, N. E., Enosi Tuipulotu, D., Eltahla, A. A., Lun, J. H., Ferla, S., Brancale, A., ... White, P. A. (2017). Broad-spectrum non-nucleoside inhibitors for caliciviruses. Antiviral Research, 146, 65-75. https://doi.org/10.1016/j.antiviral.2017.07.014
Netzler, Natalie E ; Enosi Tuipulotu, Daniel ; Eltahla, Auda A ; Lun, Jennifer H ; Ferla, Salvatore ; Brancale, Andrea ; Urakova, Nadya ; Frese, Michael ; Strive, Tanja ; Mackenzie, Jason M ; White, Peter A. / Broad-spectrum non-nucleoside inhibitors for caliciviruses. In: Antiviral Research. 2017 ; Vol. 146. pp. 65-75.
@article{4f08607ea70f43609d24b0eb015b93bc,
title = "Broad-spectrum non-nucleoside inhibitors for caliciviruses",
abstract = "Viruses of the Caliciviridae cause significant and sometimes lethal diseases, however despite substantial research efforts, specific antivirals are lacking. Broad-spectrum antivirals could combat multiple viral pathogens, offering a rapid solution when no therapies exist. The RNA-dependent RNA polymerase (RdRp) is an attractive antiviral target as it is essential for viral replication and lacks mammalian homologs. To focus the search for pan-Caliciviridae antivirals, the RdRp was probed with non-nucleoside inhibitors (NNIs) developed against hepatitis C virus (HCV) to reveal both allosteric ligands for structure-activity relationship enhancement, and highly-conserved RdRp pockets for antiviral targeting. The ability of HCV NNIs to inhibit calicivirus RdRp activities was assessed using in vitro enzyme and mouse norovirus cell culture assays. Results revealed that three NNIs which bound the HCV RdRp Thumb I (TI) site also inhibited transcriptional activities of six RdRps spanning the Norovirus, Sapovirus and Lagovirus genera of the Caliciviridae. These NNIs included JTK-109 (RdRp inhibition range: IC50 4.3-16.6 μM), TMC-647055 (IC50 range: 18.8-45.4 μM) and Beclabuvir (IC50 range: 23.8->100 μM). In silico studies and site-directed mutagenesis indicated the JTK-109 binding site was within the calicivirus RdRp thumb domain, in a pocket termed Site-B, which is highly-conserved within all calicivirus RdRps. Additionally, RdRp inhibition assays revealed that JTK-109 was antagonistic with the previously reported RdRp inhibitor pyridoxal-5'-phosphate-6-(2'-naphthylazo-6'-nitro-4',8'-disulfonate) tetrasodium salt (PPNDS), that also binds to Site-B. Moreover, like JTK-109, PPNDS was also a potent inhibitor of polymerases from six viruses spanning the three Caliciviridae genera tested (IC50 range: 0.1-2.3 μM). Together, this study demonstrates the potential for de novo development of broad-spectrum antivirals that target the highly-conserved RdRp thumb pocket, Site-B. We also revealed three broad-spectrum HCV NNIs that could be used as antiviral scaffolds for further development against caliciviruses and other viruses.",
keywords = "Antiviral Agents, Benzazepines, enzyme inhibitors, virus inhibition, Norovirus, Caliciviridae, RNA-dependent RNA polymerase, Broad-spectrum antivirals, Non-nucleoside inhibitors, Direct-acting antivirals, Antiviral Agents/chemistry, Virus Replication/drug effects, Benzazepines/pharmacology, Crystallography, X-Ray, Structure-Activity Relationship, Indoles/pharmacology, Inhibitory Concentration 50, Enzyme Inhibitors/chemistry, Caliciviridae/drug effects, RNA Replicase/antagonists & inhibitors, Animals, Benzimidazoles/pharmacology, Norovirus/drug effects, Hepacivirus/drug effects, Binding Sites/drug effects",
author = "Netzler, {Natalie E} and {Enosi Tuipulotu}, Daniel and Eltahla, {Auda A} and Lun, {Jennifer H} and Salvatore Ferla and Andrea Brancale and Nadya Urakova and Michael Frese and Tanja Strive and Mackenzie, {Jason M} and White, {Peter A}",
note = "Copyright {\circledC} 2017. Published by Elsevier B.V.",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.antiviral.2017.07.014",
language = "English",
volume = "146",
pages = "65--75",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",

}

Netzler, NE, Enosi Tuipulotu, D, Eltahla, AA, Lun, JH, Ferla, S, Brancale, A, Urakova, N, Frese, M, Strive, T, Mackenzie, JM & White, PA 2017, 'Broad-spectrum non-nucleoside inhibitors for caliciviruses', Antiviral Research, vol. 146, pp. 65-75. https://doi.org/10.1016/j.antiviral.2017.07.014

Broad-spectrum non-nucleoside inhibitors for caliciviruses. / Netzler, Natalie E; Enosi Tuipulotu, Daniel; Eltahla, Auda A; Lun, Jennifer H; Ferla, Salvatore; Brancale, Andrea; Urakova, Nadya; Frese, Michael; Strive, Tanja; Mackenzie, Jason M; White, Peter A.

In: Antiviral Research, Vol. 146, 01.10.2017, p. 65-75.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Broad-spectrum non-nucleoside inhibitors for caliciviruses

AU - Netzler, Natalie E

AU - Enosi Tuipulotu, Daniel

AU - Eltahla, Auda A

AU - Lun, Jennifer H

AU - Ferla, Salvatore

AU - Brancale, Andrea

AU - Urakova, Nadya

AU - Frese, Michael

AU - Strive, Tanja

AU - Mackenzie, Jason M

AU - White, Peter A

N1 - Copyright © 2017. Published by Elsevier B.V.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Viruses of the Caliciviridae cause significant and sometimes lethal diseases, however despite substantial research efforts, specific antivirals are lacking. Broad-spectrum antivirals could combat multiple viral pathogens, offering a rapid solution when no therapies exist. The RNA-dependent RNA polymerase (RdRp) is an attractive antiviral target as it is essential for viral replication and lacks mammalian homologs. To focus the search for pan-Caliciviridae antivirals, the RdRp was probed with non-nucleoside inhibitors (NNIs) developed against hepatitis C virus (HCV) to reveal both allosteric ligands for structure-activity relationship enhancement, and highly-conserved RdRp pockets for antiviral targeting. The ability of HCV NNIs to inhibit calicivirus RdRp activities was assessed using in vitro enzyme and mouse norovirus cell culture assays. Results revealed that three NNIs which bound the HCV RdRp Thumb I (TI) site also inhibited transcriptional activities of six RdRps spanning the Norovirus, Sapovirus and Lagovirus genera of the Caliciviridae. These NNIs included JTK-109 (RdRp inhibition range: IC50 4.3-16.6 μM), TMC-647055 (IC50 range: 18.8-45.4 μM) and Beclabuvir (IC50 range: 23.8->100 μM). In silico studies and site-directed mutagenesis indicated the JTK-109 binding site was within the calicivirus RdRp thumb domain, in a pocket termed Site-B, which is highly-conserved within all calicivirus RdRps. Additionally, RdRp inhibition assays revealed that JTK-109 was antagonistic with the previously reported RdRp inhibitor pyridoxal-5'-phosphate-6-(2'-naphthylazo-6'-nitro-4',8'-disulfonate) tetrasodium salt (PPNDS), that also binds to Site-B. Moreover, like JTK-109, PPNDS was also a potent inhibitor of polymerases from six viruses spanning the three Caliciviridae genera tested (IC50 range: 0.1-2.3 μM). Together, this study demonstrates the potential for de novo development of broad-spectrum antivirals that target the highly-conserved RdRp thumb pocket, Site-B. We also revealed three broad-spectrum HCV NNIs that could be used as antiviral scaffolds for further development against caliciviruses and other viruses.

AB - Viruses of the Caliciviridae cause significant and sometimes lethal diseases, however despite substantial research efforts, specific antivirals are lacking. Broad-spectrum antivirals could combat multiple viral pathogens, offering a rapid solution when no therapies exist. The RNA-dependent RNA polymerase (RdRp) is an attractive antiviral target as it is essential for viral replication and lacks mammalian homologs. To focus the search for pan-Caliciviridae antivirals, the RdRp was probed with non-nucleoside inhibitors (NNIs) developed against hepatitis C virus (HCV) to reveal both allosteric ligands for structure-activity relationship enhancement, and highly-conserved RdRp pockets for antiviral targeting. The ability of HCV NNIs to inhibit calicivirus RdRp activities was assessed using in vitro enzyme and mouse norovirus cell culture assays. Results revealed that three NNIs which bound the HCV RdRp Thumb I (TI) site also inhibited transcriptional activities of six RdRps spanning the Norovirus, Sapovirus and Lagovirus genera of the Caliciviridae. These NNIs included JTK-109 (RdRp inhibition range: IC50 4.3-16.6 μM), TMC-647055 (IC50 range: 18.8-45.4 μM) and Beclabuvir (IC50 range: 23.8->100 μM). In silico studies and site-directed mutagenesis indicated the JTK-109 binding site was within the calicivirus RdRp thumb domain, in a pocket termed Site-B, which is highly-conserved within all calicivirus RdRps. Additionally, RdRp inhibition assays revealed that JTK-109 was antagonistic with the previously reported RdRp inhibitor pyridoxal-5'-phosphate-6-(2'-naphthylazo-6'-nitro-4',8'-disulfonate) tetrasodium salt (PPNDS), that also binds to Site-B. Moreover, like JTK-109, PPNDS was also a potent inhibitor of polymerases from six viruses spanning the three Caliciviridae genera tested (IC50 range: 0.1-2.3 μM). Together, this study demonstrates the potential for de novo development of broad-spectrum antivirals that target the highly-conserved RdRp thumb pocket, Site-B. We also revealed three broad-spectrum HCV NNIs that could be used as antiviral scaffolds for further development against caliciviruses and other viruses.

KW - Antiviral Agents

KW - Benzazepines

KW - enzyme inhibitors

KW - virus inhibition

KW - Norovirus

KW - Caliciviridae

KW - RNA-dependent RNA polymerase

KW - Broad-spectrum antivirals

KW - Non-nucleoside inhibitors

KW - Direct-acting antivirals

KW - Antiviral Agents/chemistry

KW - Virus Replication/drug effects

KW - Benzazepines/pharmacology

KW - Crystallography, X-Ray

KW - Structure-Activity Relationship

KW - Indoles/pharmacology

KW - Inhibitory Concentration 50

KW - Enzyme Inhibitors/chemistry

KW - Caliciviridae/drug effects

KW - RNA Replicase/antagonists & inhibitors

KW - Animals

KW - Benzimidazoles/pharmacology

KW - Norovirus/drug effects

KW - Hepacivirus/drug effects

KW - Binding Sites/drug effects

UR - http://www.scopus.com/inward/record.url?scp=85028005278&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2017.07.014

DO - 10.1016/j.antiviral.2017.07.014

M3 - Article

VL - 146

SP - 65

EP - 75

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

ER -

Netzler NE, Enosi Tuipulotu D, Eltahla AA, Lun JH, Ferla S, Brancale A et al. Broad-spectrum non-nucleoside inhibitors for caliciviruses. Antiviral Research. 2017 Oct 1;146:65-75. https://doi.org/10.1016/j.antiviral.2017.07.014